Universität zu Köln

Bubendorf, Lukas, Buettner, Reinhard, Al-Dayel, Fouad, Dietel, Manfred, Elmberger, Goran, Kerr, Keith, Lopez-Rios, Fernando, Marchetti, Antonio, Oz, Buge, Pauwels, Patrick, Penault-Llorca, Frederique, Rossi, Giulio ORCID: 0000-0001-8855-1218, Ryska, Ales ORCID: 0000-0002-3051-2280 and Thunnissen, Erik (2016). Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch., 469 (5). S. 489 - 504. NEW YORK: SPRINGER. ISSN 1432-2307

Full text not available from this repository.

Abstract

Rearrangements of the ROS1 gene occur in 1-2 % of non-small cell lung cancers (NSCLCs). Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advanced ROS1-positive NSCLC. Consequently, focus on ROS1 testing is growing. Most laboratories currently rely on fluorescence in situ hybridisation (FISH) assays using a dual-colour break-apart probe to detect ROS1 rearrangements. Given the rarity of these rearrangements in NSCLC, detection of elevated ROS1 protein levels by immunohistochemistry may provide cost-effective screening prior to confirmatory FISH testing. Non-in situ testing approaches also hold potential as stand-alone methods or complementary tests, including multiplex real-time PCR assays and next-generation sequencing (NGS) platforms which include commercial test kits covering a range of fusion genes. In order to ensure high-quality biomarker testing, appropriate tissue handling, adequate control materials and participation in external quality assessment programmes are essential, irrespective of the testing technique employed. ROS1 testing is often only considered after negative tests for EGFR mutation and ALK gene rearrangement, based on the assumption that these oncogenic driver events tend to be exclusive. However, as the use of ROS1 inhibitors becomes routine, accurate and timely detection of ROS1 gene rearrangements will be critical for the optimal treatment of patients with NSCLC. As NGS techniques are introduced into routine diagnostic practice, ROS1 fusion gene testing will be provided as part of the initial testing package.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Bubendorf, Lukas UNSPECIFIED UNSPECIFIED UNSPECIFIED Buettner, Reinhard UNSPECIFIED UNSPECIFIED UNSPECIFIED Al-Dayel, Fouad UNSPECIFIED UNSPECIFIED UNSPECIFIED Dietel, Manfred UNSPECIFIED UNSPECIFIED UNSPECIFIED Elmberger, Goran UNSPECIFIED UNSPECIFIED UNSPECIFIED Kerr, Keith UNSPECIFIED UNSPECIFIED UNSPECIFIED Lopez-Rios, Fernando UNSPECIFIED UNSPECIFIED UNSPECIFIED Marchetti, Antonio UNSPECIFIED UNSPECIFIED UNSPECIFIED Oz, Buge UNSPECIFIED UNSPECIFIED UNSPECIFIED Pauwels, Patrick UNSPECIFIED UNSPECIFIED UNSPECIFIED Penault-Llorca, Frederique UNSPECIFIED UNSPECIFIED UNSPECIFIED Rossi, Giulio UNSPECIFIED orcid.org/0000-0001-8855-1218 UNSPECIFIED Ryska, Ales UNSPECIFIED orcid.org/0000-0002-3051-2280 UNSPECIFIED Thunnissen, Erik UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-258022
DOI:	10.1007/s00428-016-2000-3
Journal or Publication Title:	Virchows Arch.
Volume:	469
Number:	5
Page Range:	S. 489 - 504
Date:	2016
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-2307
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language OF-AMERICAN-PATHOLOGISTS; IN-SITU HYBRIDIZATION; TYROSINE KINASE ROS; CLINICOPATHOLOGICAL ANALYSIS; NEVER-SMOKERS; DETECTING ALK; REARRANGEMENTS; FUSION; GENE; EXPRESSION Multiple languages Pathology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/25802